Biogen has kicked off a phase 3 clinical trial to test omaveloxolone, an experimental drug, in children with Friedreich’s ataxia (FA)—a rare genetic disorder that affects movement and coordination. If successful, this could offer a much-needed treatment option for kids battling this progressive condition.

Editor’s Note: Right now, there’s no cure for FA, and treatments are limited—so a phase 3 trial is a big deal. It means the drug has already shown enough promise in earlier studies to warrant this critical step. For families affected by FA, this could be a glimmer of hope, even if it’s still early days. Biogen’s move signals progress in tackling rare diseases that often get overlooked.